アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

mylan institutional llc - ibutilide fumarate (unii: 9l5x4m5l6i) (ibutilide - unii:2436vx1u9b) - ibutilide fumarate 0.1 mg in 1 ml - ibutilide fumarate injection is indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm. patients with atrial arrhythmias of longer duration are less likely to respond to ibutilide fumarate injection. the effectiveness of ibutilide has not been determined in patients with arrhythmias of more than 90 days in duration. ibutilide fumarate injection is contraindicated in patients who have previously demonstrated hypersensitivity to ibutilide fumarate or any of the other product components.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

generamedix inc. - ibutilide fumarate (unii: 9l5x4m5l6i) (ibutilide - unii:2436vx1u9b) - ibutilide fumarate 0.1 mg in 1 ml

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

pharmacia & upjohn company llc - ibutilide fumarate (unii: 9l5x4m5l6i) (ibutilide - unii:2436vx1u9b) - ibutilide fumarate 0.1 mg in 1 ml - corvert injection is indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm. patients with atrial arrhythmias of longer duration are less likely to respond to corvert. the effectiveness of ibutilide has not been determined in patients with arrhythmias of more than 90 days in duration. corvert injection is contraindicated in patients who have previously demonstrated hypersensitivity to ibutilide fumarate or any of the other product components.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - ibutilide fumarate (unii: 9l5x4m5l6i) (ibutilide - unii:2436vx1u9b) - ibutilide fumarate injection is indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm. patients with atrial arrhythmias of longer duration are less likely to respond to ibutilide fumarate. the effectiveness of ibutilide has not been determined in patients with arrhythmias of more than 90 days in duration. life-threatening arrhythmias—appropriate treatment environment ibutilide fumarate can cause potentially fatal arrhythmias, particularly sustained polymorphic ventricular tachycardia, usually in association with qt prolongation (torsades de pointes), but sometimes without documented qt prolongation. in registration studies, these arrhythmias, which require cardioversion, occurred in 1.7% of treated patients during, or within a number of hours of, use of ibutilide fumarate. these arrhythmias can be reversed if treated promptly (see warnings, proarrhythmia). it is essential that ibutilide fumarate be administered in a setting of continuous ecg monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia. patients with atrial fibrillation of more than 2 to 3 days’ duration must be adequately anticoagulated, generally for at least 2 weeks. choice of patients patients with chronic atrial fibrillation have a strong tendency to revert after conversion to sinus rhythm (see clinical studies) and treatments to maintain sinus rhythm carry risks. patients to be treated with ibutilide fumarate , therefore, should be carefully selected such that the expected benefits of maintaining sinus rhythm outweigh the immediate risks of ibutilide fumarate , and the risks of maintenance therapy, and are likely to offer an advantage compared with alternative management. ibutilide fumarate injection is contraindicated in patients who have previously demonstrated hypersensitivity to ibutilide fumarate or any of the other product components.

オランダ - オランダ語 - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

pfizer b.v. rivium westlaan 142 2909 ld capelle a/d ijssel - ibutilide fumaraat samenstelling overeenkomend met ; ; ibutilide 87 µg/ml - oplossing voor infusie - natriumacetaat 3-water (e 262) ; natriumchloride ; natriumhydroxide (e 524) ; water, gezuiverd ; zoutzuur (e 507), - ibutilide

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

pharmacia and upjohn company - ibutilide fumarate (unii: 9l5x4m5l6i) (ibutilide - unii:2436vx1u9b) - ibutilide fumarate 0.1 mg in 1 ml

ギリシャ - ギリシャ語 - Εθνικός Οργανισμός Φαρμάκων

pfizer ΕΛΛΑΣ Α.Ε. (0000000047) Μεσογείων 243,, 154 51, Νέο Ψυχικό, 154 51 - ibutilide fumarate - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ ΓΙΑ ΕΝΔΟΦΛΕΒΙΑ ΕΓΧΥΣΗ - 0.1mg/ml(87mcg/ml) - ineof01082 ibutilide fumarate 0.100000 mg - ibutilide

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

pharmacia & upjohn company llc - ibutilide fumarate (unii: 9l5x4m5l6i) (ibutilide - unii:2436vx1u9b) - corvert injection is indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm. patients with atrial arrhythmias of longer duration are less likely to respond to corvert. the effectiveness of ibutilide has not been determined in patients with arrhythmias of more than 90 days in duration. corvert injection is contraindicated in patients who have previously demonstrated hypersensitivity to ibutilide fumarate or any of the other product components.

フランス - フランス語 - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

pfizer holding france - ibutilide - solution - 0,087 mg - composition pour 1 ml > ibutilide : 0,087 mg . sous forme de : fumarate d'ibutilide 0,100 mg - antiarythmique, classe iii

カナダ - 英語 - Health Canada

pfizer canada ulc - ibutilide fumarate - solution - 0.1mg - ibutilide fumarate 0.1mg - class iii antiarrythmics